Sodium–Glucose Cotransporter-2 Inhibitor–associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine · 2020 · 5.2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

Anne L. Peters, Elizabeth Buschur, John B. Buse et al. · Diabetes Care · 2015 · 830 citations · Full text

Medicine, Endocrinology, Pharmacology +17

16. Diabetes Care in the Hospital: <i>Standards of Medical Care in Diabetes—2022</i>

Diabetes Care · 2021 · 423 citations · Full text

Medicine, Internal Medicine, Diabetology +13

American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis

Yehuda Handelsman, Robert R. Henry, Zachary T. Bloomgarden et al. · Endocrine Practice · 2016 · 357 citations

Medicine, Endocrinology, Pharmacology +12

Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data

Jenny E. Blau, Sri Harsha Tella, Simeon I. Taylor et al. · Diabetes/Metabolism Research and Reviews · 2017 · 257 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17